文献速递肝肾功能剂量调整特殊人群用药

每周一次胰岛素Icodec的药代与药效学特性综述

Once-Weekly Insulin Icodec: A Review of its Pharmacokinetic and Pharmacodynamic Properties.
PubMed 文献 · Clin Pharmacokinet · 2026-10-26

本文综述每周一次基础胰岛素Icodec的药代动力学与药效学证据:其半衰期约7天,暴露呈剂量比例且周间可预测,个体内总暴露变异系数为5.9%;临床稳态需3-4周达到,年龄、性别、糖尿病类型、种族、肝肾功能等不影响其药理特性。

要点

  • Icodec半衰期约7天,药代与药效覆盖整个每周给药间隔。
  • 暴露呈剂量比例,个体内总暴露变异系数为5.9%。
  • 临床稳态约3-4周达到,首剂增加50%可缩短1周。

核心结论

  • Icodec的药理特性支持可预测、持续的基础胰岛素覆盖,适合每周一次给药。

研究设计与样本

  • 本综述汇总Icodec在2型或1型糖尿病人群中采用一致方法学表征的药代与药效学证据。

主要发现

  • Icodec半衰期约7天,药代和药效谱覆盖整个每周给药间隔。
  • Icodec暴露呈剂量比例,周间可预测,个体内总暴露变异系数为5.9%。
  • 降糖效果与注射部位无关。
  • 治疗启动后临床稳态在3-4周达到,若首剂增加50%可缩短1周。
  • 年龄、性别、糖尿病类型、种族、族裔、肝肾功能损害、血清白蛋白或抗胰岛素Icodec抗体水平对药理特性无临床相关影响。

临床怎么用

  • 临床可依据每周一次给药实现可预测的持续基础胰岛素覆盖。
  • 起始后需注意约3-4周才达临床稳态,首剂增加50%可缩短1周。
  • 肾功能或肝功能损害、不同年龄性别种族等患者无需基于药理特性调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Insulin icodec is a novel long-acting basal insulin engineered for once-weekly administration. Structural modifications enhance reversible albumin binding and slow insulin receptor binding, resulting in protracted exposure and glucose-lowering effect. The clinical pharmacology of icodec was characterised using consistent methodology across populations with type 2 or type 1 diabetes. Icodec has a half-life of approximately 7 days and pharmacokinetic and pharmacodynamic profiles covering the full weekly dosing interval. It displays dose-proportional exposure, week-to-week predictability, with an intra-individual coefficient of variation in total exposure of 5.9%, and a comparable glucose-lowering effect independent of injection region. Following treatment initiation, icodec clinical steady state is achieved after 3-4 weeks-this can be reduced by 1 week if the first icodec dose is 50% increased. If, unintentionally, a too high insulin dose is administered, hypoglycaemia risk with icodec is comparable to that of daily basal insulin, including robust physiological counter-regulation to hypoglycaemia. During exercise or prolonged fasting, glucose metrics remained within recommended targets, with no clinically significant or severe hypoglycaemia, and supplemental glucose, when required, effectively prevented clinically relevant hypoglycaemia. The pharmacological properties of icodec are preserved across patient characteristics, without a clinically relevant impact of age, sex, diabetes type, race, ethnicity, renal or hepatic impairment, serum albumin or anti-insulin icodec antibody level. These findings support predictable, sustained basal insulin coverage suitable for once-weekly administration. This review summarises the evidence on icodec pharmacokinetic and pharmacodynamic properties and discusses how these characteristics translate into clinical benefits and specific clinical considerations compared with existing once-daily basal insulin.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Heise T, Haridas MP, Kristensen NR, et al. Once-Weekly Insulin Icodec: A Review of its Pharmacokinetic and Pharmacodynamic Properties. Clin Pharmacokinet. 2026. PMID: 42932162. doi:10.1007/s40262-026-01719-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。